公开(公告)号：US12121555B1

公开(公告)日：2024-10-22

申请号：US18643408

申请日：2024-04-23

申请人： KING FAISAL UNIVERSITY

发明人： Abdalla Ahmed Albashir ,  Khansa Alshambatya ,  Sakina Yagia ,  Amel Yousef Ebrahim

IPC分类号： A61K36/18 ,  C12N9/99

CPC分类号： A61K36/18 ,  C12N9/99 ,  A61K2236/15 ,  A61K2236/17 ,  A61K2236/333 ,  A61K2236/35 ,  A61K2236/53

摘要： A method of inhibiting enzyme activity using an extract of Boscia senegalensis. In an embodiment, the extract is obtained from leaves of Boscia senegalensis. In an embodiment, the enzyme is one or more selected from the group consisting of acetylcholinesterase, butyrylcholinesterase, tyrosinase, α-amylase, and glucosidase.

公开(公告)号：US20240317707A1

公开(公告)日：2024-09-26

申请号：US18613350

申请日：2024-03-22

申请人： UT-Battelle, LLC ,  Northeastern University

发明人： Jerry M. Parks ,  Brian Sanders ,  Lori Ferrins

IPC分类号： C07D401/06 ,  A61K31/192 ,  A61K31/235 ,  A61K31/337 ,  A61K31/427 ,  A61P31/14 ,  C07C241/04 ,  C07D305/08 ,  C07D409/06 ,  C07D417/06 ,  C12N9/99

CPC分类号： C07D401/06 ,  A61K31/192 ,  A61K31/235 ,  A61K31/337 ,  A61K31/427 ,  A61P31/14 ,  C07C241/04 ,  C07D305/08 ,  C07D409/06 ,  C07D417/06 ,  C12N9/99 ,  C07C2602/10

摘要： A compound having the following structure:




R1 is a hydrocarbon group containing at least one aromatic or heteroaromatic ring or fused ring system, wherein the at least one aromatic or heteroaromatic ring or fused ring system is optionally substituted; R2 and R3 are independently selected from the group consisting of hydrogen (H), halogen atom, and hydrocarbon groups containing 1-6 carbon atoms and optionally substituted; R4 and R5 are independently selected from H, halogen atom, and hydrocarbon groups containing 1-6 carbon atoms and optionally substituted; R6 is H or a hydrocarbon group containing 1-12 carbon atoms and optionally containing one or more heteroatoms selected from O, N, S, and F; and Ra, Rb, Rc, and Rd are independently selected from H; halogen atom; hydrocarbon groups containing 1-3 carbon atoms; amine groups; amide groups; and —(CH2)p—T groups, wherein T is a hydrocarbon group with —NH— linkage; and pharmaceutically acceptable salts thereof.

公开(公告)号：US11971337B2

公开(公告)日：2024-04-30

申请号：US17493477

申请日：2021-10-04

申请人： Ventana Medical Systems, Inc.

发明人： James Grille ,  Brian D. Kelly ,  Jerome Kosmeder, II ,  Eric May ,  Noemi Sebastiao ,  Pamela Wirth

IPC分类号： G01N1/30 ,  A61K49/00 ,  C01B15/01 ,  C01B21/08 ,  C07C55/02 ,  C07C55/22 ,  C07C55/24 ,  C12N9/99 ,  G01N33/52

CPC分类号： G01N1/30 ,  C01B15/01 ,  C01B21/08 ,  C07C55/02 ,  C07C55/22 ,  C07C55/24 ,  C12N9/99 ,  G01N33/52 ,  A61K49/001 ,  G01N2001/302 ,  G01N2333/902 ,  G01N2333/908 ,  G01N2333/916

摘要： Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.

公开(公告)号：US11767522B2

公开(公告)日：2023-09-26

申请号：US16303684

申请日：2017-05-16

申请人： Norgen Biotek Corp.

发明人： Taha Alexander Haj-Ahmad ,  Yousef Haj-Ahmad

IPC分类号： C12Q1/6806 ,  C12N15/10 ,  C12N1/04 ,  C11D1/08 ,  C11D1/10 ,  C11D3/04 ,  C11D3/37 ,  C12N9/99

CPC分类号： C12N15/1006 ,  C11D1/08 ,  C11D1/10 ,  C11D3/046 ,  C11D3/37 ,  C12N1/04 ,  C12Q1/6806 ,  C12N9/99 ,  C12Q1/6806 ,  C12Q2527/125 ,  C12Q2527/137 ,  C12Q2527/127

摘要： Provided is a composition for preserving cell-free nucleic acids and/or cells in a biological sample and methods for use thereof. The composition comprises at least one volume excluding polymer, at least one osmotic agent and at least one enzyme inhibitor. The composition optionally further comprises at least one metabolic inhibitor. Further, provided is a kit comprising the composition, preferably in a blood collection tube, or the components of the composition.

公开(公告)号：US20220242859A1

公开(公告)日：2022-08-04

申请号：US17614847

申请日：2020-06-05

申请人： DISARM THERAPEUTICS, INC.

发明人： Robert Owen HUGHES ,  Rajesh DEVRAJ ,  Todd BOSANAC ,  Richard Andrew JARJES-PIKE ,  Andrew BREARLEY ,  Jonathan BENTLEY

IPC分类号： C07D417/04 ,  C07D275/03 ,  C07D417/10 ,  C07D417/12 ,  C07D451/02 ,  C07D487/08 ,  A61P25/28 ,  C12N9/99

摘要： The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and/or compositions that are useful in medicine, and particularly for treating neurodegeneration (e.g., for reducing axonal degeneration). In some embodiments, the present disclosure provides compounds having a structure as set forth in Formula (I).

公开(公告)号：US20220112205A1

公开(公告)日：2022-04-14

申请号：US17484739

申请日：2021-09-24

申请人： Tosk, Inc.

发明人： Solomon B. Ungashe ,  Stephen D. Yanofsky

IPC分类号： C07D491/056 ,  C07D405/10 ,  C07D401/12 ,  C07D239/84 ,  C07D405/14 ,  C07D401/14 ,  C07D519/00 ,  C07D471/04 ,  C12N9/99

摘要： RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

公开(公告)号：US20210380667A1

公开(公告)日：2021-12-09

申请号：US17284137

申请日：2019-10-08

申请人： Novozymes A/S

发明人： Poul Erik Pedersen ,  Esben Peter Friis ,  Carsten Andersen ,  Peter Rahbek Oestergaard ,  Johan Qvist

IPC分类号： C07K14/81 ,  C12P21/02 ,  C12N9/99 ,  C12N9/48

摘要： Disclosed are protease inhibitors capable of inhibiting the protease activity of a S1 or a S8 protease at ambient pH, but where the inhibitor further has a pH dependent binding to the S1 or the S8 inhibitor meaning that a complex of a S1 and a S8 protease and the inhibitor dissociates when pH is lowered to a pH below 6.0, e.g. to a pH value in the range of 4.0 to 6.0; e.g. in the range of 4.5 to 6.0; e.g. in the range of 4.5 to 5.5; whereby the protease activity is released.

公开(公告)号：US10695349B2

公开(公告)日：2020-06-30

申请号：US16529213

申请日：2019-08-01

申请人： ICOS Corporation

发明人： Chanchal Sadhu ,  Ken Dick ,  Jennifer Treiberg ,  C. Gregory Sowell ,  Edward A. Kesicki ,  Amy Oliver

IPC分类号： C07C233/66 ,  A61K31/506 ,  C07D403/12 ,  C07D473/00 ,  C07D473/16 ,  C07D473/24 ,  C07D473/30 ,  C12N9/99 ,  C07D473/38 ,  C07D473/40 ,  C07D487/04 ,  C12N9/12 ,  C07D473/32 ,  C07D473/34 ,  C07D233/66

摘要： Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

公开(公告)号：US20200061062A1

公开(公告)日：2020-02-27

申请号：US16529213

申请日：2019-08-01

申请人： ICOS Corporation

发明人： Chanchal SADHU ,  Ken DICK ,  Jennifer TREIBERG ,  C. Gregory SOWELL ,  Edward A. KESICKI ,  Amy OLIVER

IPC分类号： A61K31/506 ,  C07D403/12 ,  C07D473/00 ,  C07D473/16 ,  C07D473/24 ,  C07D473/30 ,  C07D473/34 ,  C07D473/38 ,  C07D473/40 ,  C07D487/04 ,  C12N9/12 ,  C07D473/32 ,  C12N9/99

摘要： Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

公开(公告)号：US10550178B2

公开(公告)日：2020-02-04

申请号：US16117700

申请日：2018-08-30

申请人： Srikanth Vedamoorthy

发明人： Srikanth Vedamoorthy

IPC分类号： A61K39/395 ,  C12N5/07 ,  C12N5/16 ,  C12N9/02 ,  C07K16/00 ,  C12P21/08 ,  C07K16/18 ,  C12N9/96 ,  C12N9/99 ,  C12N9/00 ,  C12N9/04 ,  C12P21/00 ,  C12P21/02 ,  A61K38/00 ,  C07K16/44 ,  A61K39/00

摘要： An isolated antibody, consisting of an anti-glutathionylated eNOS antibody, wherein the anti-glutathionylated eNOS antibody has been generated against an immunogen consisting of a peptide that includes glutathione; a first linker; an eNOS peptide; a second linker; and a T-cell epitope; and wherein the anti-glutathionylated eNOS antibody is adapted to recognize redox modulated eNOS proteins.